慢性肝功能失代偿发生于众多肝脏疾病的终末阶段，以肝移植作为首选治疗手段，因供体不足无法满足需求。近来通过移植组织前体细胞治疗不同器官纤维化伴发功能失代偿取得良好的效果，但如何在慢性肝损伤治疗中提高肝前体细胞再生功能及移植效率，及其分子调控机制亟需进一步研究。我们前期发现体外通过小分子重编程，可诱导成熟肝细胞转化为肝前体样细胞，移植后可定植于受损肝脏并重建功能；近期我们进一步研究发现肝前体样细胞均表达CD24并伴随Notch信号通路活化。本项目拟通过应用小分子组合将小鼠成熟肝细胞重编程为肝前体细胞，明确CD24分子维持肝前体细胞自我更新及生物学特性的作用；探索Notch通路活化对肝前体细胞CD24表达和功能的影响；进而通过不同小分子组合介导Notch通路活化或抑制，靶向调控CD24阳性肝前体样细胞转化，在不同肝损伤疾病模型中，干预乃至逆转肝功能失代偿的发展进程,为肝病治疗提供新的靶点和思路。

Chronic liver dysfunction occurs in numerous terminal stage of liver disease, however liver transplantation, the preferred treatment for liver dysfuction, is far from satisfactory due to organ deficiency. Although recently some researches have successfully tried the transplantation of stem cells or progenitor cells to rescue organ dysfunction with fibrosis , whether mature hepatocyte-derived liver progenitor cells (LPCs) have therapeutic effects in chronic hepatic insufficiency remains unknown. We have previously found that small molecules can be used to induce conversion of mature hepatocytes into progenitor cells in vitro, with proliferation, redifferentiation and repopulation capabilities. Furthermore, these cells highly express CD24 and Notch signal pathway is also up-regulated. Here, we focus on the application of small molecules-induced hepatocyte-to-LPC conversion. Firstly our purpose is to figure out the role of CD24 in regulating biological characteristics of LPCs. Then based on the models of Liver dysfunction, this study will reveal how activation of Notch pathway influences the expression of CD24. Finally, the combinations of small molecules, alteration of Notch signaling pathway, which targets to regulate the conversion of CD24 + LPCs, may intervene or even reverse the development process of liver dysfunction. Our studies may provide a novel method for the treatment of chronic liver dysfunction.